Hopes raised by new HIV treatment

Fix energy prices until 30th September 2017

Looking to switch your business energy supplier? Click here

Use our OFGEM accredited comparison tool to compare the whole market today.

A new antiretroviral drug could "substantially" improve survival rates among people living with HIV, it has been claimed.

According to a Spanish study published today in the Lancet medical journal, a combination of the protease inhibitor darunavir and a low dose of existing antiretroviral drug ritonavir resulted in two-thirds of test subjects experiencing a tenfold reduction in HIV RNA levels – the genetic material that constitutes HIV.

In comparison, only 15 per cent of a control group of HIV sufferers receiving conventional treatments reached this proportion during the 48-week long study.

Dr Bonaventura Clotet of Barcelona's Hospital Universitari and his team say there is an "urgent need" for improved HIV-treating drugs due to the sizeable rates of failure in existing drug combinations.

The scientists say that over six-year periods, one in five HIV patients will be failed by their medication.

In an accompanying article, Dr Rodger MacArthur of Wayne State University in Detroit, Michigan cautioned that a further comparison between darunavir-ritonavir and tripranavir-ritonavir would be necessary to determine the true effectiveness of the new treatment.

But he added: "For now, all of us treating HIV-infected individuals in clinical practice will probably rejoice in the availability of darunavir, since it seems to be a safe, well-tolerated, and truly effective agent against multi-drug resistant HIV."

Click here to run an energy price comparison, and see if you could be paying less for your gas and electricity.

Found this page interesting?

Help spread the word and share this page with your friends and family on your social networks.